Reversion mutations in BRCA1 or BRCA2 genes: Resistant mechanism(s) in patients treated with platinumbased agents or poly (ADP-ribose) polymerase (PARP) inhibitors.


Sourat Darabi, David R. Braxton, Joanne Xiu, Benedito A. Carneiro, Jeffrey Swensen, Emmanuel S. Antonarakis, Stephen V. Liu, Rana R. McKay, David Spetzler, Wafik S. El-Deiry, Michael J. Demeure

Key Finding:

The rate of reversion mutations following PARP inhibitor or platinum-based therapy is low among BRCA1/2 mutated tumors (1.0- 2.5%), possibly due to the lack of profiling post-treatment. Repeating tumor profiling at times of treatment resistance can help inform therapy selection in the refractory disease setting. 

Download Publication